Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | XBP1 | P17861 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725616 | 1.00 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3728417 | 1.00 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL31645354 | 0.98 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL18342541 | 0.98 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL5753572 | 0.98 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL30902877 | 0.90 | CA12 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL5801336 | 0.88 | CA14 (0.46) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL13223287 | 0.86 | CA12 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3185669 | 0.81 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL10892359 | 0.81 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570813-A1 | METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | SPARK BIOPHARMA, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240209020-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2024-06-27 | — | — | US | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024080333-A1 | METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-04-18 | — | — | WO | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20140179917-A1 | PREPARATION OF MAYTANSINOID ESTERS | BIO-THERA SOLUTIONS, LTD., CO. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| CN-1950328-A | Phenyl indan derivatives | LUNDBECK & CO AS H (DK) | 2007-04-18 | — | — | CN | disclosed |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| EP-1322596-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2002024629-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | CA12 2086/4885CA14 2594/4885DGAT1 3584/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | CA12 4586/4885CA14 4710/4885DGAT1 4804/4885 |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | TYR, TPST2, COMT | CA12 4594/4885CA14 4542/4885DGAT1 2607/4885 |
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | MYD88, MYADM, CD14 | CA12 4572/4885CA14 4122/4885DGAT1 4746/4885 |
| US-20240209020-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | NAAA, FAAH, FAAH2 | CA12 270/4885CA14 311/4885DGAT1 328/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | CA12 4118/4885CA14 4012/4885DGAT1 3280/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | CA12 2459/4885CA14 2107/4885DGAT1 2103/4885 |
| US-20140179917-A1 | PREPARATION OF MAYTANSINOID ESTERS | WEE1, WEE2, CRH | CA12 496/4885CA14 123/4885DGAT1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.